Results 221 to 230 of about 6,667,826 (304)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study. [PDF]

Cancers (Basel)
Zhang X, Li X, Liu J, Huang B, Gu J, Chen M, Kuang L, Li J.   +7 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Liquid Biopsy for Molecular Residual Disease Detection and Postoperative Surveillance in Gastric Cancer: Current Evidence and Future Directions. [PDF]

Int J Mol Sci
Lazaridou L, Vakalou K, Dimaki A, Koumarelas KE, Zachos K, Schizas D, Christodoulidis G.   +6 more
europepmc   +1 more source

Minimal Residual Disease [PDF]

, 2018
openaire   +2 more sources

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Real-world evidence of measurable residual disease assessment in multiple myeloma. [PDF]

Blood Adv
Cedena MT, Puig N, Paiva B, de la Puerta JE, Pérez-Montaña A, Casanova M, Breña J, García A, de Arriba F, Martínez-Chamorro C, Sirvent M, Blanchard MJ, Alonso R, Álvarez MÁ, Capote FJ, García-Sánchez R, Pérez JJ, Rodriguez-Otero P, Lahuerta JJ, Martínez-López J, Martínez-López J, Mateos MV, San-Miguel J.   +22 more
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence. [PDF]

J Liq Biopsy
Verzè M, Minari R, Bordi P, Bocchialini G, Martines G, Pluchino M, D'Agnelli S, Gnetti L, Cosenza A, Balestra V, Ampollini L, Leo L, Milanese G, Roberti C, Gallani C, Hayes J, Malapelle U, Tiseo M.   +17 more
europepmc   +1 more source

Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling

Molecular Oncology, EarlyView.
This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan, Beatriz Martín‐Gracia, Eva Bassols‐Citores, Krizia Sagini, Maria K. Andersen, Tuula A. Nyman, May‐Britt Tessem, Morten B. Rye, Alicia Llorente   +8 more
wiley   +1 more source